Béguelin et al., Impact of tenofovir on hepatitis delta virus replication
Impact of tenofovir on hepatitis delta replication in HIV-coinfected patients in the Swiss HIV Cohort Study. Clinical Infectious Diseases Béguelin et al. assessed the impact of long-term Tenofovir Disoproxil Fumarat (TDF) therapy on hepatitis B virus (HBV) and hepatitis delta virus (HDV) replication in the Swiss HIV Cohort Study (SHCS). All SHCS participants with […]
Trickey et al., Mortality after 10 years of ART
Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. PLoS One Trickey et al. on behalf of the Antiretroviral Therapy Cohort Collaboration aimed to estimate mortality rates and prognostic factors in HIV-positive patients who started combination antiretroviral therapy (cART) between 1996–1999 and survived for more than ten years. During 50’593 person […]
Marzel et al., Raisons principales des nouvelles infections avec le VIH, selon l’Etude suisse de cohorte VIH
La transmission du VIH pendant les 12 premiers mois après la contamination ou à la suite d’un arrêt du traitement VIH sont les raisons principales des nouvelles infections avec le VIH, selon l’Etude suisse de cohorte VIH. Clinical Infectious Diseases Les personnes sous thérapie antirétrovirale efficace qui prennent régulièrement leurs médicaments anti-VIH ne peuvent […]
Marzel et al., Motivi principali di nuove infezioni HIV in Svizzera
La trasmissione dell’HIV nei primi 12 mesi dopo il contagio o dopo un’interruzione della terapia antiretrovirale sono i motivi principali di nuove infezioni HIV in Svizzera. Clinical Infectious Diseases Le persone trattate per l’HIV che assumono fedelmente farmaci antiretrovirali non trasmettono l’HIV ad altre persone. Durante i primi mesi dopo il contagio, il rischio […]
Marzel et al., Hauptgründe für neue HIV-Infektionen in der SHCS
HIV-Übertragungen durch Personen in den ersten 12 Monaten nach Ansteckung oder nach Stoppen der HIV-Therapie sind die Hauptgründe für neue HIV-Infektionen in der Schweizerischen HIV Kohortenstudie. Clinical Infectious Diseases Es gilt, dass Personen unter einer wirksamen HIV-Therapie und regelmässiger Einnahme ihrer HIV-Medikamente das HIV sexuell nicht mehr auf andere Personen übertragen können. Zudem ist […]
Gebreselassie et al., Travel to the tropics and HIV viral control
Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travellers to the tropics in the Swiss HIV Cohort Study. HIV Medicine Gebreselassie et al. aimed to describe the characteristics of the population in the Swiss HIV Cohort Study (SHCS) travelling to the tropics and to determine the frequency and risk factors of […]
Bader et al., Immune function suppresses X4-tropic HIV
Therapeutic immune recovery and reduction of CXCR4-tropic HIV-1. Clinical Infectious Diseases Bader et al. aimed at assessing the tropism of viral integrates in 35 HIV-positive patients’ blood during fully suppressive combination antiretroviral therapy (cART) by applying next-generation sequencing. The relative frequencies of proviral X4-tropic HIV-1 variants decreased or stayed stable over time in the […]
Fidler et al., Predictors of post treatment control after stopping ART
Virological blips and predictors of post treatment viral control after stopping ART started in Primary HIV infection. Journal of Acquired Immune Deficiency Syndromes Fidler et al. on behalf of CASCADE collaboration in EuroCoord explored the frequency, magnitude, and predictive value of measured viral blips on the probability of achieving post treatment control (PTC) among […]
Scherrer et al., L’apparizione di resistenze dell’HIV contro i medicamenti antiretrovirali è praticamente scomparsa in Svizzera
L’apparizione di resistenze dell’HIV contro i medicamenti antiretrovirali è praticamente scomparsa in Svizzera – un’analisi dei risultati dello Studio Svizzero della Coorte HIV su un periodo di 15 anni. Clinical Infectious Diseases È risaputo che l’assunzione di farmaci per l’HIV poco efficaci o l’assunzione irregolare dei farmaci favorisce l’insorgenza di resistenze. Le resistenze […]
Scherrer et al., Auftreten von erworbenen Resistenzen von HIV gegenüber HIV-Medikamenten in der CH beinahe gänzlich gestoppt
Das Auftreten von erworbenen Resistenzen von HIV gegenüber HIV-Medikamenten hat in der Schweiz beinahe gänzlich gestoppt – eine Analyse von Daten aus der Schweizerischen HIV Kohortenstudie über den Zeitraum von 15 Jahren. Clinical Infectious Diseases Es ist bekannt, dass bei HIV-infizierten Personen der Einsatz von ungenügend wirksamen HIV-Medikamenten oder die unregelmässige Einnahme derselben zu […]